177 related articles for article (PubMed ID: 33737678)
21. [Oxcarbazepine in the treatment of epilepsy. A review and update].
Horga de la Parte JF; Horga A
Rev Neurol; 2006 Jan 16-31; 42(2):95-113. PubMed ID: 16450324
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy.
Kim DW; Gu N; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Kim HS; Oh J; Lee SK
Epilepsia; 2012 Jan; 53(1):e9-12. PubMed ID: 22091603
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
24. [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].
Steinhoff BJ; Stefan H; Schulze-Bonhage A; Hueber R; Paulus W; Wangemann M; Elger CE
Nervenarzt; 2012 Oct; 83(10):1292-9. PubMed ID: 22850688
[TBL] [Abstract][Full Text] [Related]
25. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Wegner I; Wilhelm AJ; Sander JW; Lindhout D
Epilepsy Behav; 2013 Oct; 29(1):217-21. PubMed ID: 23995050
[TBL] [Abstract][Full Text] [Related]
26. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine.
Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A
Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
[TBL] [Abstract][Full Text] [Related]
28. [Oxcarbazepine].
Arroyo S
Neurologia; 2001 Oct; 16(8):370-5. PubMed ID: 11738014
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of oxcarbazepine 10-monohydroxy derivative in Chinese adult epileptic patients.
Yang Q; Hu Y; Zhang X; Zhang X; Dai H; Li X
Eur J Hosp Pharm; 2023 Mar; 30(e1):e90-e96. PubMed ID: 35787526
[TBL] [Abstract][Full Text] [Related]
30. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy.
Park KJ; Kim JR; Joo EY; Seo DW; Hong SB; Ko JW; Kim SR; Huh W; Lee SY
Clin Neuropharmacol; 2012; 35(1):40-4. PubMed ID: 22246398
[TBL] [Abstract][Full Text] [Related]
31. Plasma level monitoring of oxcarbazepine in epileptic patients.
González-Esquivel DF; Ortega-Gavilán M; Alcántara-López G; Jung-Cook H
Arch Med Res; 2000; 31(2):202-5. PubMed ID: 10880728
[TBL] [Abstract][Full Text] [Related]
32. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial.
Beydoun A; Sachdeo RC; Rosenfeld WE; Krauss GL; Sessler N; Mesenbrink P; Kramer L; D'Souza J
Neurology; 2000 Jun; 54(12):2245-51. PubMed ID: 10881247
[TBL] [Abstract][Full Text] [Related]
33. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC
Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597
[TBL] [Abstract][Full Text] [Related]
34. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Rhee SJ; Shin JW; Lee S; Moon J; Kim TJ; Jung KY; Park KI; Lee ST; Jung KH; Yu KS; Jang IJ; Chu K; Lee SK
Epilepsy Res; 2017 May; 132():8-14. PubMed ID: 28279893
[TBL] [Abstract][Full Text] [Related]
37. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy.
Barcs G; Walker EB; Elger CE; Scaramelli A; Stefan H; Sturm Y; Moore A; Flesch G; Kramer L; D'Souza J
Epilepsia; 2000 Dec; 41(12):1597-607. PubMed ID: 11114219
[TBL] [Abstract][Full Text] [Related]
38. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
[TBL] [Abstract][Full Text] [Related]
39. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
[TBL] [Abstract][Full Text] [Related]
40. Analysis of influencing factors on monohydroxylated derivative of oxcarbazepine plasma concentration in children with epilepsy.
Yao N; Huang S; Huang A; Song H
Eur J Clin Pharmacol; 2022 Oct; 78(10):1667-1675. PubMed ID: 36006433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]